Active substances
Hydrocortisone + Pramoxine
- US FDA 8
- Health Canada 2
- US price lines 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PRAMOSONE | 0.5%;1% | cream · topical | LEGACY | Prescription | 13 Aug 1976 |
| PRAMOSONE | 1%;1% | cream · topical | LEGACY | Prescription | 7 Jan 1977 |
| PRAMOSONE | 2.5%;1% | lotion · topical | LEGACY | Prescription | 5 Jun 1978 |
| PRAMOSONE | 1%;1% | lotion · topical | LEGACY | Prescription | 5 Jun 1978 |
| PROCTOFOAM HC | 1%;1% | aerosol, metered · topical | MYLAN SPECIALITY LP | Prescription | 26 Jul 1978 |
| EPIFOAM | 1%;1% | aerosol, metered · topical | MYLAN SPECIALITY LP | Prescription | 19 Dec 1979 |
| PRAMOSONE | 0.5%;1% | lotion · topical | FERNDALE LABS | Discontinued | 13 Nov 1973 |
| HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1% | 1%;1% | aerosol, metered · topical | GENUS | Discontinued | 17 May 1988 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| PRAMOX HC CREAM | 00770957 | 1 %; 1 % | CREAM · TOPICAL | DERMTEK PHARMA INC |
| PRAMOX HC LOTION | 01954210 | 1 %; 1 % | LOTION · TOPICAL | DERMTEK PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PROCTOFOAM-HC 1%-1% FOAM | $19.38171 | per GM | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.